Systematic review of the evidence for the use of DOAC's in patient with a heart transplant.

What is it about?

While DOACs have become a more favorable alternative to warfarin in the general population for a variety of indications, the efficacy and safety in OHT patients is less well understood. The risks and benefits of DOAC therapy in this specialized patient population must be carefully evaluated before deciding to initiate treatment with a DOAC. Limited studies address the safety and efficacy of DOACs in solid-organ transplant recipients, so it is likely that real world data from larger observational studies, despite their limitations, will inform clinicians with decision making in the future. Until then, the risks and benefits of the use of DOACs in OHT patients should be carefully evaluated on an individual basis.

Featured Image

Why is it important?

Systematic review of all the published literature and summary of the potential drug interaction concerns in the post-heart transplant population.

Perspectives